Prevention of human immunodeficiency virus-related opportunistic infections in France: A cost-effectiveness analysis

Clinical Infectious Diseases

Volumn 36, Issue 1, 2003, Pages 86-96

  Yazdanpanah, Yazdan ^a,e   Goldie, S J ^f   Paltiel, A D ^d   Losina, E ^f   Coudeville, L ^a   Weinstein, M C ^f   Gerard, Y ^f   Kimmel, A D ^c   Zhang, H ^c   Salamon, R ^b   Mouton, Y ^f   Freedberg, K A ^c  

^a CNRS   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTRE HOSPITALIER DE TOURCOING   (France)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; COTRIMOXAZOLE; EFAVIRENZ; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; ATYPICAL MYCOBACTERIOSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIMULATION; TOXOPLASMOSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; FRANCE; GUIDELINES; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; QUALITY OF LIFE;

EID: 0037232717     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344902     Document Type: Article

References (45)

1. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-6.
2. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl 1):S5-14.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
4. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30(Suppl 1):S29-65.
5. Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med 2002; 162:921-8.
6. Paltiel AD, Goldie SJ, Losina E, et al. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis 2001; 32:783-93.
7. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997; 17:373-81.
8. Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130-6.
9. Yazdanpanah Y, Goldie SJ, Salamon R, Mouton Y, Freedberg KA. Are European-specific guidelines needed for prevention of opportunistic infections in HIV-1? Lancet 1999; 354:1305-6.
10. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH. Paris: Flammarion, 1999.
11. Dormont J. Prise en charge des personnes atteintes par le VIH. Paris: Flammarion, 1996.
12. Davies J, Everall IP, Weich S, et al. HIV-associated brain pathology: a comparative international study. Neuropathol Appl Neurobiol 1998; 24:118-24.
13. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384-91.
14. Schweitzer SO. Pricing pharmaceuticals in a world environment. In: Schweitzer SO, ed. Pharmaceuticals economics and policy. New York: Oxford University Press, 1997:137-51.
15. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-50.
16. Freedberg KA, Losina E, Weinstein MC, et al. The cost-effectiveness of combination antiretroviral therapy in HIV. N Engl J Med 2001; 344:824-31.
17. Collège des Economistes de ta Santé. Recommendations de bonnes pratiques des méthodes d'évaluation économique des stratégies thérapeutiques. Journal d'Économie Médicale 1997; 16:329-51.
18. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
19. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
20. Yazdanpanah Y, Chene G, Losina E, et al. Incidence of primary opportunistic infections in two HIV-infected French clinical cohorts. Int J Epidemiol 2001; 30:864-71.
21. Munoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol 1993; 137:423-38.
22. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A metaanalysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156:177-88.
23. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329:828-33.
24. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:700-5.
25. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334:1491-7.
26. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
27. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-73.
28. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392-8.
29. Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antiviral Ther (in press).
30. Nomenclature des actes de biologie médicale. Paris: Union des Caisses Nationales de Sécurité Sociale, 1997.
31. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-9.
32. Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982; 30:1043-69.
33. Paltiel D, Scharfstein JA, Seage G, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 1998; 18(Suppl):S93-105.
34. Drug topics red book. Montvate, NJ: Medical Economics, 2000.
35. Chaix C, Grenier-Sennelier C, Clevenbergh P, et al. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J Acquir Immune Defic Syndr 2000; 24:227-31.
36. Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med 2001; 2:52-8.
37. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-24.
38. 3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991; 4:521-31.
39. Sendi PP, Craig BA, Meier G, et al. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretrovirat therapy. The Swiss HIV Cohort Study. J Antimicrob Chemother 1999; 44:811-7.
40. Moore RD. Cost-effectiveness of prophylaxis for Mycobacterium avium complex disease. Am J Med 1997; 102:50-5.
41. Freedberg KA, Cohen CJ, Barber TW. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:275-82.
42. Bayoumi AM, Redelmeier DA. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. AIDS 1998; 12:1503-12.
43. Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 1998; 26:186-7.
44. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995; 35:103-14.
45. Miller V, Sabin CA, Phillips AN, et al. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000; 14:2129-36.